PD-L1 is expressed on the surface of tumor cells and prevention of binding its inhibitory receptor PD-1 on T cells by mAb monotherapies was shown to have pronounced anti-tumor activity in clinical trials [14, 15]. This evidence concerns the gene CD274 and neoplasm.